▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2476 by analyst upside · 2026-06-27
PCRX
Pacira BioSciences, Inc.
Healthcare · Market Cap $993M · P/E 194.2x
ANALYST PRICE TARGET
+17.5%
implied upside to consensus target
Current Price $25.24
Consensus Target $29.67
Bull Target $38.0
Bear Target $23.0
Analysts Covering 6
ANALYST CONSENSUS — BUY
Strong Buy
1
Buy
3
Hold
2
Sell
0
52-Week Low $18.8
52-Week High $27.64
YTD Return +3.2%
FUNDAMENTALS
Market Cap $993M
P/E Ratio (TTM) 194.2x
Forward P/E 6.9x
EPS (TTM) $0.13
PEG Ratio 11.21
Dividend Yield N/A
Revenue (TTM) $735M
Profit Margin 0.7%
52-WEEK RANGE
52-Week Low $18.8
52-Week High $27.64
Current Price $25.24
Bear Target $23.0
Bull Target $38.0
● Now $25.24 ● Target $29.67
TRADING DATA
Avg Volume 522K
YTD Return +3.2%
Analyst Count 6
Consensus Buy
Upside to Target +17.5%
Last Updated 2026-06-27

ANALYST SUMMARY

Pacira BioSciences, Inc. (PCRX) is currently trading at $25.24 with a Wall Street consensus price target of $29.67, implying potential upside of 17.5% over the next 12 months. 6 analysts currently cover PCRX, with a consensus rating of Buy — 67% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $38.0, while the most cautious has a target of $23.0.

PCRX operates in the Healthcare sector with a market capitalisation of $993M. The stock is up 3.2% year-to-date and is currently trading near the upper end of its 52-week range of $18.8 – $27.64.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

USPH +36.2%
U.S. Physical Therapy, Inc.
$1B · P/E 132.3x · Buy
OMCL +52.7%
Omnicell, Inc.
$2B · P/E 91.2x · Buy
PNTG +13.7%
The Pennant Group, Inc.
$1B · P/E 41.8x · Buy
HSTM +19.7%
HealthStream, Inc.
$781M · P/E 38.2x · Buy
TBRG -2.9%
TruBridge, Inc.
$393M · P/E 90.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for PCRX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

RBC Capital — Reiterated
Sector Perform → Sector Perform 2026-05-01 Building track record
Needham — Reiterated
Buy → Buy 2026-05-01 20% win rate (5 calls)
Barclays — Reiterated
Equal-Weight → Equal-Weight 2026-03-26 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-01-09 31% win rate (48 calls)
Needham — Reiterated
Buy → Buy 2026-01-09 20% win rate (5 calls)
Barclays ● Initiated
Equal-Weight 2025-12-09 Building track record
Truist Securities — Reiterated
Buy → Buy 2025-11-07 Building track record
Needham — Reiterated
Buy → Buy 2025-05-09 20% win rate (5 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →